Serum Institute of India Invests in IntegriMedical
Serum
Institute of India (SII) has announced a strategic investment in
IntegriMedical, acquiring a 20% stake in the company, to advance Needle-Free
Injection System technology.
The
partnership between SII and IntegriMedical aligns with SII's vision of 'Health
for All' and IntegriMedical's mission to ‘Transform Healthcare Globally’ by
providing patient comfort, ensuring increased patient compliance, reducing
needle-stick injuries, and enhancing the efficacy of liquid medication via
needle-free dispersion.
IntegriMedical
has developed a US patented Needle-Free Injection System (N-FIS) that utilises
high-velocity jet stream using mechanical power to effectively and consistently
administer biologics and drugs. The innovative drug delivery solution aims to
alleviate pain during administration, providing needle-phobic patients with a
pleasant and stress-free experience.
Comments
Post a Comment